Danish Biotech Stock News

cBrain arrived at this earnings print with a strong recent share run and a valuation that already reflected high growth expectations. The stock closed at DKK74 after the report, leaving investors to weigh a familiar software trade off. Revenue for H1 2026 came in at DKK140.0m with net income of DKK27.9m, while the trailing 12 month net margin sits at 18.1%, below the prior year level. The central question is whether that margin pressure reflects a temporary investment choice or a more...

Dampskibsselskabet Norden (CPSE:DNORD) drew fresh attention after reporting second quarter 2026 sales of US$1,047.4 million and net income of US$100.8 million, alongside a higher floor for its full year net profit guidance. See our latest analysis for Dampskibsselskabet Norden. The strong second quarter update and raised guidance appear to sit behind a clear upswing in Dampskibsselskabet Norden's share price, with a 6.45% 1 month share price return and a 39.66% year to date share price...

A week ago, FLSmidth & Co. A/S ( CPH:FLS ) came out with a strong set of quarterly numbers that could potentially lead...

The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...

ALK-Abelló stock went into the earnings release under pressure, down roughly 20% over the past three months, yet the latest numbers tell a more resilient story. The company just posted trailing twelve month revenue of DKK 6,561m and earnings from continuing operations of DKK 1,280m, with a net profit margin near 19.5%. The key question for you now is whether that profit profile justifies a P/E of about 36x in a sector where many peers trade at far lower multiples. The rest of the earnings...

GN Store Nord stock came into this earnings print under pressure, down about 12% over the past week and weaker over the past quarter as well. The headline from Q2 is not a growth story. The group booked a loss from continuing operations and reported basic earnings per share of DKK 1.56 in the red, even though revenue from continuing operations reached DKK 2,171m. The key issue for investors is the balance sheet and valuation strain. Net interest bearing debt of DKK 9.6b remains heavy, while...

Columbus stock closed at DKK9.8 heading into the first full trading day after its earnings release, with recent returns only slightly in the red over one, three and six months. The headline from the numbers is not growth. It is the squeeze on profitability. Trailing net profit margin is 0.4% compared with 2.9% a year earlier, and earnings in the most recent year turned negative, even as revenue stayed in the billion-krona range. For an IT services company, that gap between volume and profit...

The market came into GrønlandsBANKEN’s Q2 numbers with the stock drifting, down about 7% over the past month and slightly weaker over the past week. Yet the headline from these results is not the share price; it is the squeeze on profitability in a bank already wrestling with elevated bad loans. Revenue for Q2 landed at DKK 117.429 million while net income came in at DKK 45.864 million, well below the strong Q1 run rate. For a bank often viewed through a value lens, with a P/E of 10.4x and a...

The market has barely flinched on Lån & Spar Bank, with the stock almost flat over the last month despite a clear earnings jolt in Q2. Basic earnings per share jumped to DKK36.80 as net income reached DKK127.21m, putting profit strength at the center of this release. For a bank already trading on a P/E of 11.3x and priced well below some valuation estimates, that level of profitability sets up a sentiment clash. Short term price action looks cautious, while the Q2 numbers highlight an...

Lollands Bank comes into this earnings season with a stock that has been quietly grinding higher, up about 2.1% over the past week and 2.5% over three months, while trading on a modest P/E of 10.4x. The headline from Q2 is simple: profitability is the story. Net profit margins over the last year sit at 30.8% compared with 29.5% a year earlier, and earnings have risen 3.3% over that period. For a regional bank, that margin profile is the key tension between the muted share price moves and what...

Novozymes stock went into today on a strong run, with the share price up about 17% over the past three months and trading on a rich P/E near 45x. That kind of optimism sets a high bar. The earnings headline is clear. Organic sales in the first half grew 8% with adjusted earnings before interest, tax, depreciation and amortization margin at 37.7%, and management lifted full year organic growth guidance to 7 to 8% with margin expected at the top of the 37 to 38% range. Is Novozymes at 45x P/E a...

Carlsberg stock has drifted lower in recent weeks, with the share price down about 7% over the past month even as H1 results landed with solid headline growth. The earnings story that matters most is not the revenue print. It is the squeeze on profitability that shows up in a trailing net margin of 7.1% compared with 8.1% a year earlier. Short term traders are reacting to the chart. Long term holders are more likely focused on a company that still carries a premium P/E multiple and high debt,...

Kreditbanken entered this earnings day with a strong equity story in the bank sector. The stock closed at DKK9,750 on 20 August after a solid run over the past quarter, and the fresh Q2 numbers show that the real action is in the income statement, not the chart. The headline is profitability. Net income for Q2 came in at DKK40.5 million on revenue of DKK101.6 million, while trailing 12 month net profit margin sits at 41%. For a stock trading on a trailing P/E of 11.1x, that combination of...

UIE went into this earnings print with a market profile that looked confused. The stock closed at DKK391 on 20 August, with a rich 21.1x P/E and yet a discount to a much higher cash flow valuation. That tension met a quarter where the headline story is profit quality rather than breakneck growth. Q2 2026 basic earnings per share landed at US$1.21 on net income of US$37.17m, a clean rebound from the loss in Q1. For you as an investor, the question now is how durable that margin recovery really...

The market has cooled on H. Lundbeck in recent months, with the stock down about 5% over 30 days and closing at DKK40.64 yesterday, even as the long term story has often centered on underappreciated value. Q2 2026 results land squarely in that expectation gap. Revenue of DKK6,463m and basic earnings per share of DKK1.16 tell a quieter quarterly story, yet the trailing P/E of 10.2x versus far higher industry averages and a discounted cash flow value estimate above DKK100 keep the valuation...

Rockwool stock has been treading water in recent weeks, roughly flat over one and three months. The latest earnings reminder is blunt: the company is still loss making on a trailing 12 month view, even as Q2 delivered €1,009m in revenue and €93m in net income from ongoing operations. The short term story is a stock that already trades on a rich sales multiple and sits well above a cited discounted cash flow value. The longer term question for you is whether the expected earnings recovery can...

Vestas Wind Systems (CPSE:VWS) drew investor attention after reporting second quarter 2026 earnings, with higher sales and net income than a year earlier, while also raising EBIT margin guidance for the full year. See our latest analysis for Vestas Wind Systems. The earnings release and raised margin outlook appear to be contributing to building momentum in Vestas Wind Systems, with a 30 day share price return of 15.19% and a 1 year total shareholder return of 56.28% from a lower base, even...

Trifork Group AG ( CPH:TRIFOR ) shareholders are probably feeling a little disappointed, since its shares fell 9.8% to...

Royal Unibrew A/S ( CPH:RBREW ) shareholders are probably feeling a little disappointed, since its shares fell 6.2% to...

FLSmidth stock came into this earnings print on a strong run, up about 16% over the past month and modestly higher over three months, which indicates sentiment was already warm. The headline today is clear: the market got a capital goods company with real operating traction, not just a story. Order intake in key service and mining pump lines grew at double digit organic rates, and the adjusted earnings before interest, tax and amortisation margin landed at 17.3%. That is a quality...

Jyske Bank stock closed at DKK1,040 today, roughly flat over the past week after a strong 3 month run, and that calm surface hides a sharper earnings story. The headline is simple. The bank printed one of its strongest profit runs in recent years with trailing net income of DKK4,943m and a net margin of 34.9%, while the market still values it on a 12x P/E and a sizeable discount to a DCF based fair value estimate. Emotion looks muted; the numbers suggest a more confident mood. If you like...

Coloplast stock closed at DKK441.8 on Wednesday, only modestly higher over the past week and month, even after investors digested a quarter that quietly reset the earnings narrative. The headline is a sharp profit rebound. Q3 basic earnings per share landed at 6.49 DKK with net income of DKK1,462m and total revenue of DKK7,355m. The market still carries the scar of the recent one off loss that dragged the trailing net margin down to 7.5%. Today’s calm price action suggests investors are...

Novo Nordisk (CPSE:NOVO B) is back in focus after its CEO argued that investors may be undervaluing the long term potential of obesity treatments, along with fresh signals on the company’s shareholder return plans. See our latest analysis for Novo Nordisk. Novo Nordisk’s recent CEO comments and ongoing buyback and dividend plans come after a mixed run, with the share price up 2.76% over 90 days but down 10.17% over 30 days and the 1 year total shareholder return declining 10.80%, while the 3...

Coloplast (CPSE:COLO B) is in focus after third quarter earnings, which showed organic revenue and EBIT growth and a reaffirmed full year outlook, despite ongoing reimbursement pressure in the Biologics segment. See our latest analysis for Coloplast. At a share price of DKK435.6, Coloplast has seen a 3.0% 1 day share price return and a 5.8% 90 day share price return, while the 5 year total shareholder return is down 54.4%. This suggests that recent momentum has improved compared with a weaker...